FIELD: pharmaceutics; medicine.
SUBSTANCE: invention relates to the field of pharmaceutics and medicine; it is aimed at the treatment of inflammatory conditions. The use of a composition containing amount of a selective agonist of a retinoic acid receptor γ (hereinafter – RARγ), sufficient for inhibition of activation of anti-inflammatory NKT cells type I for the treatment or prevention of at least one inflammatory condition mediated with NKT cells type I is disclosed, where the specified selective RARγ agonist is more efficient in terms of action on at least RARγ, compared to RARα.
EFFECT: invention provides efficient inhibition of activation of anti-inflammatory NKT cells type I for the treatment or prevention of an inflammatory condition.
5 cl, 1 tbl, 19 ex, 18 dwg
